Antibody discovery is central to modern biologics research, advancing both clinical research and targeted therapies. Antibodies can precisely bind to antigens, making them powerful tools in treating cancer, autoimmune disorders, neurological conditions, and infectious diseases. Over the years, evolving antibody discovery technologies have improved how therapeutic antibodies are developed, by boosting safety, precision, and accessibility. These technological innovations have expanded the scope of antibody drugs, from classic formats to advanced designs, and reshaped discovery pipelines in both research and commercial markets.
Advancements in this field have introduced multiple approaches for generating antibodies with high specificity, improved functionality, and diverse therapeutic applications.
Introduced in the 1970s, hybridoma technology was the first method to enable the production of monoclonal antibodies. This technique involves immunizing a mouse with an antigen to trigger an immune response, followed by the fusion of the mouse's spleen cells with myeloma cells to create hybrid cells, or hybridomas. Each hybridoma secretes a specific monoclonal antibody, which can be identified and harvested. This technology's significance lies in its ability to produce large quantities of identical antibodies, which are crucial for research, diagnostic, and therapeutic applications. However, the limitations include the complexity of the process and the ethical considerations regarding animal use.
Phage display technology, recognized with a share of the 2018 Nobel Prize in Chemistry for its applications in peptides and antibodies, has been instrumental in the discovery and development of humanized and fully human antibodies. By inserting a gene encoding an antibody or peptide into a bacteriophage, researchers can screen vast libraries for those that bind to a specific target. This technology has facilitated the rapid identification of antibody candidates with high specificity and affinity, leading to the development of several FDA-approved therapeutic antibodies, including the first fully human antibody, adalimumab (Humira).
Yeast display technology is a powerful platform for antibody engineering and discovery. It utilizes yeast cells to express proteins, including antibodies, on their surface. Similar to phage display, it supports engineering for improved binding and stability, facilitating the design of specialized formats such as antibody-drug conjugates and immune checkpoint inhibitors.
One advantage of yeast display is the ability to perform post-translational modifications on displayed antibodies, which can be crucial for proper function. Additionally, while the library sizes tend to be smaller than phage display, yeast display can be particularly useful for identifying antibodies that are difficult to isolate using other methods due to its ability to handle complex protein structures.
Single B cell technology represents a significant leap forward in antibody discovery. By isolating specific B cells from an individual, scientists can directly obtain the genetic information needed to produce monoclonal antibodies, bypassing the need for hybridoma formation. This method is valuable because it allows researchers to access the diversity of the immune response present within a single B cell, which can be crucial for developing treatments against various targets, including rapidly evolving pathogens.
The integration of artificial intelligence and machine learning has accelerated candidate identification and optimization. Techniques such as AI-assisted antibody design enable prediction of structure, affinity, and antibody-antigen interactions before lab testing. These scientific advancements reduce experimental workloads and enhance precision in antibody drug development.
Additionally, computational tools can design novel antibody sequences with desired properties, opening new avenues for therapeutic antibody development. It's important to note that computational methods are still evolving, and experimental validation remains a crucial step in antibody discovery.
Ongoing industry shifts are reshaping how therapies are researched and developed, from monoclonal antibodies to next-generation formats.
High-throughput (HTP) screening technologies have revolutionized the efficiency of antibody discovery, allowing researchers to rapidly test millions of antibody variants for their binding properties. Advances in robotics, microfluidics, and imaging have contributed to this trend, significantly reducing the time and cost associated with identifying promising antibody candidates. For example, Biointron’s HTP VHH (single-domain) antibody discovery platform takes only two weeks to complete. These technologies often work hand-in-hand with high throughput antibody production, enabling the generation of large quantities of antibodies in a short timeframe to support both research and clinical applications.
The development of multi-specific antibodies, capable of binding to more than one antigen simultaneously, has opened new possibilities for targeted therapies. These innovative molecules can engage multiple pathways involved in diseases, offering potential for more effective treatments with fewer side effects. Biointron has produced tens of thousands of bispecific antibodies, and we take pride in our ability to cater to any client request, offering a wide array of formats in bispecific antibody production.
Next-generation sequencing has transformed the understanding of the antibody repertoire, providing unprecedented insights into the diversity and evolution of antibody responses. NGS technologies enable the deep sequencing of B cell populations, facilitating the discovery of rare but therapeutically relevant antibodies.
AI-driven platforms streamline antibody discovery services by predicting structure, optimizing affinity, and suggesting candidates most likely to succeed in clinical trials. These methods are becoming central to modern antibody discovery technologies strategies.
From monoclonal antibodies to bispecific antibodies and antibody-drug conjugates, the field is evolving rapidly. The combination of antibody discovery technologies, large-scale antibody discovery services, and precision antibody drug development is paving the way for a new generation of therapeutic antibodies. With faster discovery pipelines, more effective antibody drugs, and stronger results in clinical trials, these therapies promise to deliver targeted, life-changing solutions to patients worldwide.
A VHH library is a collection of variable domains of heavy-chain antibodies (VHH……
Biointron is proud to announce the launch of the Biointron Quarterly Travel Gran……
Read a recap of the 16th World ADC San Diego 2025 conference that was held in Sa……
VHH libraries are collections of single-domain antibodies (also called nanobodie……
You can also contact us on the Scientist and Science Exchange marketplaces.
